Zentalis Pharmaceuticals, Inc.
NASDAQ: ZNTL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Julia Marie Eastland
- Employees
- 106
- Headquarters
- San Diego, United States
- IPO year
- 2020
- Market cap
- $282.6M
- Website
- https://www.zentalis.com
Loading ZNTL…
Loading profile data…Frequently asked questions about ZNTL
What does Zentalis Pharmaceuticals, Inc. (ZNTL) do?
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the...
Where does ZNTL trade?
Zentalis Pharmaceuticals, Inc. (ZNTL) trades on the NASDAQ.
What sector is ZNTL in?
Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zentalis Pharmaceuticals, Inc.?
Julia Marie Eastland is the chief executive officer of Zentalis Pharmaceuticals, Inc. (ZNTL).
Where is Zentalis Pharmaceuticals, Inc. headquartered?
Zentalis Pharmaceuticals, Inc. is headquartered in United States.
Does ZNTL pay a dividend?
Zentalis Pharmaceuticals, Inc. (ZNTL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZNTL go public?
Zentalis Pharmaceuticals, Inc. (ZNTL) completed its initial public offering in 2020.